Affinage

CPT1A

Carnitine O-palmitoyltransferase 1, liver isoform · UniProt P50416

Length
773 aa
Mass
88.4 kDa
Annotated
2026-06-09
100 papers in source corpus 40 papers cited in narrative 40 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CPT1A is the rate-limiting outer mitochondrial membrane enzyme of long-chain fatty acid oxidation (FAO), transferring long-chain acyl groups from acyl-CoA to carnitine to generate acylcarnitines for inner-membrane import, and is allosterically inhibited by malonyl-CoA (PMID:31900483). It does not act alone in the membrane: it assembles into a complex with long-chain acyl-CoA synthetase (ACSL) and the channel VDAC that funnels activated fatty acids through the outer membrane (PMID:21622568), and the CPT1A–VDAC1 interaction is itself required for normal mitochondrial permeability and respiration (PMID:37977042). Malonyl-CoA sensitivity and catalysis converge on defined residues—malonyl-CoA and the antagonist butyryl-CoA both bind Arg243 (PMID:34035164), a covalent inhibitor engages Cys96 (PMID:37977042), and a disease-causing R595W substitution disrupts protein architecture remote from the catalytic pocket (PMID:23430932). Beyond its catalytic role, CPT1A is a moonlighting protein: it possesses lysine succinyltransferase activity that modifies and stabilizes diverse substrates including S100A10, mitochondrial fission factor MFF, ATG16L1, and HSD17B10 to influence migration, lipid desaturation, autophagy, and mitochondrial RNase P stability (PMID:30394687, PMID:39956875, PMID:37961047, PMID:39038923), and it serves as a scaffold that recruits ZDHHC4 to palmitoylate MAVS at Cys79, stabilizing innate immune signaling (PMID:38016475). CPT1A also anchors Bcl-2 at the mitochondria through its BH3 domain in an activity-dependent manner to restrain apoptosis (PMID:34413485), and binds PHB2 to promote PINK1/Parkin-dependent mitophagy (PMID:37042471). Through the acetyl-CoA generated by FAO, CPT1A links lipid catabolism to epigenetic regulation, supplying acetyl groups for histone acetylation and Wnt/β-catenin and VEGFR3 signaling (PMID:32913185, PMID:31547059, PMID:29940537). CPT1A expression is transcriptionally driven by PPARα and PGC-1α through independent intronic elements (PMID:20638986) and by FOXA1 (PMID:38128823), controlled epigenetically via HDAC1/p300 and DNA methylation (PMID:31654770), and its protein stability is governed by USP50-mediated deubiquitination downstream of mitochondrial STAT3/NF-κB (PMID:34976224) and SIRT1-mediated deacetylation at Lys675 (PMID:37293270). Physiologically, CPT1A-mediated FAO mediates liver–adipose crosstalk via the PPARα–FGF21 axis (PMID:34675003), regulates AgRP-neuron control of feeding and energy balance (PMID:36966335), drives neutrophil chemotaxis (PMID:36513703), and is protective in renal and cardiac disease models (PMID:33465052, PMID:38506804), though tissue-specific knockouts reveal substantial functional redundancy with peroxisomal β-oxidation in kidney tubules and dispensability in T cells (PMID:38516886, PMID:30043753).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 2009 High

    Established CPT1A as the rate-limiting, malonyl-CoA-inhibited enzyme that commits long-chain fatty acids to mitochondrial oxidation, defining the baseline catalytic function on which all later work builds.

    Evidence Synthesis of enzymatic activity and biochemical studies in a comprehensive review

    PMID:31900483

    Open questions at the time
    • Does not resolve residue-level determinants of malonyl-CoA sensitivity or catalysis
    • Review context rather than a single new experiment
  2. 2010 High

    Resolved how CPT1A transcription is controlled, showing PPARα and PGC-1α act through separate, non-cooperating intronic elements rather than a single regulatory module.

    Evidence Luciferase reporters, intronic element mutagenesis, ligand treatment, shRNA, and in vivo rat liver transfection

    PMID:20638986

    Open questions at the time
    • Does not address protein-level or epigenetic regulation
    • Defined in rat gene; human element conservation not tested here
  3. 2011 High

    Showed CPT1A is not an isolated enzyme but a member of an outer-membrane ACSL–VDAC complex, providing a structural basis for channeling activated fatty acids across the membrane.

    Evidence Blue native PAGE, MS, and reciprocal Co-IP from liver mitochondria

    PMID:21622568

    Open questions at the time
    • Stoichiometry and architecture of the complex not determined
    • Functional channeling proposed but not directly reconstituted
  4. 2012 Medium

    Linked CPT1A to a Mendelian metabolic disorder by defining how a homozygous R595W substitution impairs enzyme activity through steric disruption rather than catalytic-site loss.

    Evidence Activity assay in patient fibroblasts plus structural modeling

    PMID:23430932

    Open questions at the time
    • No crystal structure to confirm modeled steric clash
    • Single patient genotype
  5. 2018 Medium

    Revealed the first moonlighting enzymatic function of CPT1A—lysine succinyltransferase activity—by showing it succinylates and stabilizes S100A10 to promote cancer cell invasion.

    Evidence Co-IP, MS site identification, succinyl-mimetic mutant, invasion assays, SIRT5 desuccinylation

    PMID:30394687

    Open questions at the time
    • Single lab; catalytic mechanism of succinyltransferase activity not dissected
    • Relationship to the canonical acyltransferase active site unclear
  6. 2018 High

    Demonstrated a non-enzymatic trafficking role by showing CPT1A binds Rab14 to deliver fatty acids from lipid droplets to mitochondria, coupling lipid handling to radioresistance.

    Evidence LC-MS/MS, reciprocal Co-IP, proximity ligation, BODIPY-C16 pulse-chase, Rab14 knockdown

    PMID:29721083

    Open questions at the time
    • Direct binding interface not mapped
    • Generality beyond NPC cells untested
  7. 2018 High

    Tempered overinterpretation of FAO in immunity by genetically showing CPT1A is largely dispensable for T cell differentiation and that etomoxir effects are CPT1A-independent.

    Evidence T cell-specific Cpt1a knockout with multiple subset readouts and etomoxir comparison

    PMID:30043753

    Open questions at the time
    • Does not exclude roles in other immune cell types
    • Compensatory pathways not characterized
  8. 2019 Medium

    Connected CPT1A-derived acetyl-CoA to epigenetic reprogramming, showing FAO supplies acetyl groups for histone acetylation supporting castration-resistant prostate cancer growth.

    Evidence Overexpression/knockdown, histone acetylation analysis, p300 inhibitor rescue

    PMID:31547059

    Open questions at the time
    • Single lab; direct acetyl-CoA flux to histones not traced
    • Specific histone loci not defined
  9. 2019 High

    Established epigenetic control of CPT1A transcription, mapping HDAC1 recruitment via SP1/HNF4α and p300-mediated reversal by butyrate at defined promoter regions.

    Evidence In vivo and in vitro ChIP with ethanol and butyrate treatment

    PMID:31654770

    Open questions at the time
    • Does not address protein-level regulation
    • Studied in alcoholic steatosis context
  10. 2021 High

    Provided active-site resolution of CPT1A regulation by showing butyryl-CoA competes with malonyl-CoA at Arg243 to activate FAO and drive iTreg differentiation.

    Evidence In vitro activity assays, Arg243 mutagenesis, ACSS2 inhibition, iTreg and colitis models

    PMID:34035164

    Open questions at the time
    • Structural basis of dual-ligand binding at Arg243 not crystallographically resolved
  11. 2021 High

    Established CPT1A FAO as sufficient to protect against tissue injury, showing tubular Cpt1a gain-of-function restores oxidative metabolism and suppresses renal fibrosis across three models.

    Evidence Conditional transgenic knock-in mouse, three fibrosis models, palmitate oxidation and ATP assays

    PMID:33465052

    Open questions at the time
    • Sufficiency shown by overexpression; loss-of-function necessity addressed separately and later contested
  12. 2021 High

    Defined a systemic CPT1A function by showing hepatic Cpt1a loss activates the PPARα–FGF21 axis to drive adipose browning, establishing liver–adipose metabolic crosstalk.

    Evidence Liver-specific knockout, RNAseq, anti-FGF21 neutralization, metabolic phenotyping

    PMID:34675003

    Open questions at the time
    • Mechanism linking hepatic FAO loss to PPARα-FGF21 induction not fully resolved
  13. 2022 High

    Identified protein-stability control of CPT1A, linking mitochondrial STAT3/NF-κB to USP50-mediated deubiquitination that sustains FAO during sepsis.

    Evidence MS, reciprocal Co-IP, ChIP at USP50 promoter, knockdown, knock-in mouse

    PMID:34976224

    Open questions at the time
    • E3 ligase opposing USP50 not identified
    • Direct CPT1A ubiquitination sites not mapped
  14. 2022 Medium

    Extended CPT1A FAO into innate immunity and cell behavior, showing it is required for neutrophil chemotaxis and drives clathrin expression for osteoclast fusion via C/EBPβ.

    Evidence Pharmacologic inhibition in pneumonia model; ChIP at CLTA/CLTC promoters and fusion assays

    PMID:35273614 PMID:36513703

    Open questions at the time
    • Chemotaxis effect relies on pharmacology rather than genetics
    • C/EBPβ link is single-lab
  15. 2023 High

    Uncovered a scaffolding function in innate immune signaling, showing CPT1A recruits ZDHHC4 to palmitoylate MAVS at Cys79, shifting ubiquitination to stabilize MAVS and amplify type I interferon.

    Evidence Multiple Co-IPs, palmitoylation assays, MAVS Cys79 mutagenesis, K48/K63 ubiquitination analysis, in vivo tumor models

    PMID:38016475

    Open questions at the time
    • How CPT1A bridges mitochondrial and ER-localized ZDHHC4 spatially is unclear
  16. 2023 High

    Defined CPT1A as a direct apoptosis and mitophagy regulator, anchoring Bcl-2 via its BH3 domain and modulating the PHB2–PARL interaction to promote PINK1/Parkin mitophagy.

    Evidence Co-IP, activity inhibition, macrophage-specific Bcl-2 deletion, fibrosis model; PHB2 Co-IP with M593S gain-of-function mutant in db/db cardiomyopathy

    PMID:34413485 PMID:37042471

    Open questions at the time
    • Bcl-2 anchoring data are High-confidence; PHB2/mitophagy axis is single-lab Medium
    • Whether catalytic activity and scaffolding are separable not fully resolved
  17. 2023 High

    Showed CPT1A FAO confers immune evasion and stemness across cancers, sustaining prosurvival signaling against CTL/CAR-T killing and feeding β-catenin and VEGFR3 epigenetic programs through acetyl-CoA.

    Evidence CPT1A knockout, IFN-γ/AMPK manipulation, co-culture cytotoxicity, CAR-T tumor models; acetyl-CoA and H3K9ac analyses with acetate rescue

    PMID:29940537 PMID:32913185 PMID:37722058

    Open questions at the time
    • Cancer-context dependence of these effects not generalized
    • Multiple downstream readouts from single labs
  18. 2024 High

    Challenged the necessity of mitochondrial CPT1A FAO in kidney, showing tubular knockout is dispensable due to compensatory peroxisomal β-oxidation, contrasting with earlier sufficiency claims.

    Evidence Tubule-specific knockout, multiple injury models, 2-year aging, snRNA-seq, palmitate oxidation assays

    PMID:38516886

    Open questions at the time
    • Extent of peroxisomal compensation in other tissues unknown
  19. 2024 Medium

    Expanded CPT1A's post-translational and post-transcriptional regulatory network, defining m6A/IGF2BP1/ALKBH5 control of CPT1A mRNA stability and reciprocal c-Myc and ferroptosis-suppressing axes.

    Evidence Me-RIP, mRNA stability assays, Co-IP, ubiquitination assays, knockout mice across cancer and macrophage models

    PMID:38453925 PMID:38479704 PMID:39734009

    Open questions at the time
    • Feedback loops supported with limited step-by-step mutagenesis
    • Each axis is single-lab
  20. 2025 Medium

    Consolidated CPT1A as a multifunctional succinyltransferase, showing MFF succinylation drives membrane-contact-site formation and SREBP1/SCD1 lipid desaturation for cancer stemness.

    Evidence Co-IP, succinylation assays, SREBP1/SCD1 analysis, Glyburide LSTase inhibition, stemness assays

    PMID:39956875

    Open questions at the time
    • Catalytic mechanism and substrate selectivity of LSTase activity remain undefined
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how a single protein partitions between its acyltransferase, succinyltransferase, scaffolding, and trafficking activities, and whether these are structurally separable or competing functions in the same molecule.
  • No structure capturing CPT1A in its various functional states
  • No mutant that selectively abolishes succinyltransferase while preserving FAO
  • Tissue-specific dominance of each function unmapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 5 GO:0140096 catalytic activity, acting on a protein 3 GO:0098772 molecular function regulator activity 2 GO:0016787 hydrolase activity 1
Localization
GO:0005739 mitochondrion 4
Pathway
R-HSA-1430728 Metabolism 3 R-HSA-168256 Immune System 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-9612973 Autophagy 2
Partners
ATG16L1BCL-2C-MYCPHB2RAB14S100A10VDAC1ZDHHC4
Complex memberships
CPT1A-ACSL-VDAC outer membrane complex

Evidence

Reading pass · 40 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 CPT1A exists in the liver mitochondrial outer membrane as part of a large protein complex containing long-chain acyl-CoA synthetase (ACSL) and voltage-dependent anion channel (VDAC), identified by blue native electrophoresis, immunoblotting, mass spectrometry, and reciprocal immunoprecipitation. This complex is proposed to transfer activated fatty acids through the outer mitochondrial membrane. Blue native PAGE, immunoblotting, mass spectrometry, co-immunoprecipitation with antisera against each protein The Journal of biological chemistry High 21622568
2010 PPARα activates CPT1A transcription through a binding site in the second intron of the rat CPT1A gene, while PGC-1α activates CPT1A through a separate element in the first intron; these two regulators act via independent gene elements and do not cooperate through each other's binding sites. Luciferase reporter assays, PPARα binding site mutation, WY14643 ligand treatment, PGC-1α shRNA knockdown, in vivo fasted rat liver transfection Molecular and cellular endocrinology High 20638986
2018 CPT1A interacts with Rab14, and this interaction facilitates fatty acid trafficking from lipid droplets to mitochondria in NPC cells, thereby reducing radiation-induced lipid accumulation and maximizing ATP production to promote radiation resistance. LC-MS/MS protein identification, co-immunoprecipitation, immunofluorescence, in situ proximity ligation assay, computational docking, pulse-chase fatty acid trafficking assay with BODIPY C16 and MitoTracker Red, Rab14 knockdown Theranostics High 29721083
2021 Butyrate is converted by ACSS2 to butyryl-CoA (BCoA), which antagonizes the binding of malonyl-CoA at Arg243 of CPT1A, thereby upregulating CPT1A activity and promoting fatty acid oxidation and iTreg differentiation. Mutation of CPT1A Arg243 impairs both malonyl-CoA and butyryl-CoA binding, identifying this residue as the responsible site. In vitro CPT1A activity assays, site-directed mutagenesis of Arg243, ACSS2 inhibitor, iTreg differentiation assays, mouse colitis model Proceedings of the National Academy of Sciences of the United States of America High 34035164
2018 CPT1A functions as a lysine succinyltransferase (LSTase), interacting with S100A10 and succinylating it at Lys47, which stabilizes S100A10 by suppressing ubiquitylation and proteasomal degradation, thereby promoting gastric cancer cell invasion and migration. Desuccinylation is mediated by SIRT5. Co-immunoprecipitation, mass spectrometry identification of succinylation site, succinylation mimetic mutant (K47E) overexpression, cell invasion/migration assays, knockdown experiments Journal of cellular and molecular medicine Medium 30394687
2022 Mitochondrial STAT3 stabilizes CPT1A protein by abrogating its ubiquitination and degradation in LPS-treated macrophages. This stabilization is mediated through CPT1A interaction with ubiquitin-specific peptidase 50 (USP50), whose promoter is bound by NF-κB (downstream of mitochondrial STAT3), thereby linking mitochondrial STAT3 to FAO-dependent metabolic reprogramming in sepsis. Mass spectrometry, co-immunoprecipitation (CPT1A–USP50 interaction), ChIP assay (NF-κB at USP50 promoter), USP50 knockdown, metabolic assays, knock-in mouse model Theranostics High 34976224
2023 CPT1A recruits the ER-localized palmitoyltransferase ZDHHC4 to catalyze MAVS palmitoylation at Cys79, which promotes MAVS stabilization and activation by inhibiting K48-linked ubiquitination while facilitating K63-linked ubiquitination, thereby amplifying the type I interferon response. This is a non-FAO enzymatic function of CPT1A. Co-immunoprecipitation (CPT1A–ZDHHC4 and CPT1A–MAVS), palmitoylation assays, mutagenesis of MAVS Cys79, ubiquitination assays (K48 vs K63), genetic overexpression/depletion, in vivo tumor models Molecular cell High 38016475
2021 CPT1A-dependent fatty acid oxidation promotes β-catenin acetylation and nuclear translocation in colon cancer cells exposed to adipocytes or fatty acids, activating Wnt/β-catenin target genes associated with cancer stemness. CPT1A siRNA knockdown, β-catenin nuclear translocation assays, p300 inhibitor rescue, 3D organoid culture, in vivo xenograft Cell death & disease Medium 32913185
2019 CPT1A overexpression in prostate cancer cells increases histone acetylation by supplying acetyl groups, supporting castration-resistant growth; this histone acetylation increase is partially reversed by a p300-specific inhibitor, indicating a link between lipid catabolism and epigenetic regulation. CPT1A overexpression and knockdown cell lines, histone acetylation analysis, p300 inhibitor treatment, androgen deprivation experiments, tumor growth assays Cells Medium 31547059
2021 Cpt1a overexpression in renal tubular epithelial cells (TECs) restores oxidative metabolism and mitochondrial number, increases palmitate oxidation and ATP levels, reduces fibrotic marker expression and macrophage influx in three mouse models of renal fibrosis, establishing that gain-of-function in CPT1A-mediated FAO is sufficient to protect against fibrosis. Conditional transgenic CPT1A knock-in mouse, three fibrosis models (UUO, FAN, adenine nephrotoxicity), palmitate oxidation assays, ATP measurements, histology, gene expression The Journal of clinical investigation High 33465052
2023 CPT1A-dependent FAO in cancer cells is induced by T cell-derived IFN-γ in an AMPK-dependent manner and confers resistance to cytotoxic T lymphocyte killing by maintaining prosurvival signaling. Genetic repression or pharmacologic inhibition of CPT1A renders tumors more susceptible to CAR-T cell therapy. CPT1A knockout and knockdown, IFN-γ treatment, AMPK inhibition, co-culture cytotoxicity assays, CAR-T cell therapy in tumor-bearing mice Proceedings of the National Academy of Sciences of the United States of America High 37722058
2023 CPT1A directly binds PHB2 in the mitochondria and modulates the PHB2-PARL interaction; increased CPT1A activity (induced by L-carnitine or amino acid mutation M593S) enhances the PHB2-PARL interaction and thereby promotes PINK1-Parkin-dependent mitophagy, improving mitochondrial function in diabetic cardiomyopathy. Co-immunoprecipitation (CPT1A–PHB2), adenovirus-mediated overexpression of WT and M593S mutant CPT1A, PARL overexpression rescue, immunofluorescence, transmission electron microscopy, db/db mouse model Acta physiologica (Oxford, England) Medium 37042471
2021 Hepatocyte-specific Cpt1a knockout in mice activates the PPARα-FGF21 axis, elevating circulating FGF21, which drives adipose browning and increased energy expenditure; antibody-mediated FGF21 neutralization abolishes these effects, establishing a CPT1A-mediated liver-adipose cross-talk pathway. Liver-specific Cpt1a knockout mice, RNAseq, anti-FGF21 antibody neutralization, metabolic phenotyping, adipose tissue analysis Diabetes High 34675003
2023 CPT1A directly interacts with Bcl-2 at its BH3 domain, anchoring Bcl-2 in the mitochondria in an activity-dependent manner to attenuate apoptosis in lung macrophages; disruption of this interaction induces apoptosis and reduces pulmonary fibrosis. Co-immunoprecipitation, CPT1A activity inhibition, Bcl-2 macrophage-specific deletion, bleomycin fibrosis mouse model, ABT-199 pharmacologic inhibition Cell death and differentiation High 34413485
2019 Ethanol induces repressive H3K9 deacetylation at the CPT1A promoter via HDAC1 recruitment mediated by SP1 (proximal region) and HNF4α (distal region); butyrate/tributyrin inhibits HDAC1 and facilitates p300 binding at these same sites, restoring CPT1A transcription and reducing hepatic steatosis. Chromatin immunoprecipitation (ChIP) in vivo (mouse liver) and in vitro (primary hepatocytes), ethanol and butyrate treatment, histone modification analysis Cellular and molecular gastroenterology and hepatology High 31654770
2023 SIRT1 directly deacetylates CPT1A at Lys675, which suppresses ubiquitin-dependent degradation of CPT1A and promotes FAO; berberine increases SIRT1 expression, which in turn increases CPT1A protein level and activity to alleviate NAFLD. Co-immunoprecipitation (SIRT1–CPT1A) in HEK293T cells, CPT1A activity assay, site identification at Lys675, SIRT1 overexpression/knockdown Gastroenterology report Medium 37293270
2018 High-fructose feeding induces hypermethylation of the CPT1A promoter region, associated with reduced CPT1A mRNA expression and hepatic lipid accumulation in rats. qAMP restriction digestion and real-time PCR methylation analysis, real-time PCR for mRNA quantification, rat dietary model Biochemical and biophysical research communications Low 26519879
2018 High-fat diet elevates hepatic Cpt1a expression through coordinated epigenetic mechanisms: reduced DNA methylation and increased H3K4Me2 upstream/within the promoter, accompanied by increased PPARα, C/EBPβ, PGC-1α, and BAF60a (SMARCD1) binding in the first intron at the transcription start site region. Bisulfite sequencing (DNA methylation), ChIP (H3K4Me2, PPARα, C/EBPβ, PGC-1α, BAF60a), rat dietary model, NEFA-treated H4IIEC3 hepatoma cells Biochimica et biophysica acta. Gene regulatory mechanisms Medium 30605728
2020 Liver-targeted AAV delivery of a permanently active mutant form of human CPT1A (hCPT1AM) enhances hepatic FAO and autophagy, reduces liver steatosis, and improves glucose homeostasis in a mouse model of established obesity and NAFLD. AAV9-hCPT1AM gene delivery, FAO assays, lipidomic analysis, metabolic phenotyping in HFD mice FASEB journal Medium 32666604
2009 CPT1A catalyzes the rate-limiting step of long-chain fatty acid oxidation: transfer of long-chain acyl groups from acyl-CoA to carnitine, generating acylcarnitines that cross the inner mitochondrial membrane. The enzyme is inhibited allosterically by malonyl-CoA. Review synthesizing enzymatic activity assays and biochemical studies (multiple prior studies summarized in review context) Endocrinology High 31900483
2018 Genetic deletion of Cpt1a specifically in T cells demonstrates that the ACC2/Cpt1a axis is largely dispensable for effector, memory, and regulatory T cell formation, and that the effects of etomoxir on T cell differentiation are independent of Cpt1a expression. T cell-specific Cpt1a genetic knockout mice, primary/memory/regulatory T cell functional assays, etomoxir treatment comparison Cell metabolism High 30043753
2024 CPT1A restrains ubiquitination and degradation of c-Myc, while c-Myc transcriptionally activates CPT1A expression, forming a positive feedback loop that activates the NRF2/GPX4 antioxidant system and downregulates ACSL4, thereby suppressing ferroptosis in lung cancer stem cells. Lung epithelial-specific Cpt1a-knockout mouse model, metabolomics, transcriptomics, co-immunoprecipitation (CPT1A–c-Myc), ubiquitination assays, NRF2/GPX4/ACSL4 expression analysis Signal transduction and targeted therapy Medium 38453925
2023 A novel covalent inhibitor DHP-B binds to Cys96 of CPT1A, blocks FAO, and disrupts the mitochondrial CPT1A-VDAC1 protein interaction, leading to increased mitochondrial permeability and reduced oxygen consumption in colorectal cancer cells. Covalent binding characterization, Cys96 identification, CPT1A-VDAC1 co-immunoprecipitation, oxygen consumption assay, mitochondrial permeability measurement, in vitro and in vivo tumor models Redox biology Medium 37977042
2022 CPT1A-mediated FAO in osteoclast precursors promotes their fusion by increasing expression of clathrin heavy chain (CLTC) and clathrin light chain A (CLTA) through enhanced binding of transcription factor C/EBPβ to CLTA and CLTC promoters, thereby driving clathrin-dependent endocytosis and podosome formation. CPT1A overexpression/knockdown, C/EBPβ ChIP at CLTA/CLTC promoters, clathrin expression analysis, osteoclast fusion and podosome assays, RA patient samples Frontiers in immunology Medium 35273614
2023 CPT1A loss reduces acetyl-CoA production, which decreases histone acetylation and epigenetically reprograms BCAA catabolism, leading to BCAA accumulation and hyperactivation of mTOR signaling in TP53-mutant hepatocellular carcinoma; this renders cells sensitive to the mTOR inhibitor AZD-8055. CPT1A genetic ablation (de novo liver tumor and xenograft models), acetyl-CoA measurement, histone acetylation analysis, BCAA metabolomics, mTOR pathway analysis, mTOR inhibitor treatment Cancer letters Medium 38823763
2023 FOXA1 transcriptionally promotes CPT1A expression by binding a cis-inducible element in the CPT1A promoter, as demonstrated by ChIP and dual-luciferase reporter assays; FOXA1-mediated CPT1A upregulation promotes FAO and alleviates ferroptosis in renal tubular epithelial cells under diabetic conditions. Chromatin immunoprecipitation assay, dual-luciferase reporter gene assay, FOXA1 overexpression/knockdown, CPT1A activity and FAO assays, diabetic mouse model Molecular and cellular endocrinology Medium 38128823
2025 CPT1A uses its lysine succinyltransferase (LSTase) activity to succinylate mitochondrial fission factor (MFF), which promotes mitochondria-associated membrane formation and SREBP1 activation, leading to SCD1 upregulation and lipid desaturation essential for ovarian cancer stem cell stemness maintenance. Co-immunoprecipitation (CPT1A–MFF), succinylation assays, SREBP1 activation assays, SCD1 expression analysis, LSTase activity inhibition with Glyburide, in vitro and in vivo stemness assays Communications biology Medium 39956875
2022 Cpt1a-dependent mitochondrial fatty acid oxidation is required for neutrophil chemotaxis; pharmacologic inhibition of Cpt1a impairs chemoattractant signal amplification, blunts neutrophil trafficking to sites of infection, and increases susceptibility to bacterial pneumonia in mice. Pharmacologic Cpt1a inhibition in murine pneumonia model, neutrophil chemotaxis assays, human phenome association study for pneumonia risk variant Communications biology Medium 36513703
2023 CPT1A in AgRP neurons is required for sex-dependent regulation of food intake, energy expenditure, and fluid balance; male Cpt1aKO mice show altered food intake while female Cpt1aKO mice show increased energy expenditure and brown adipose tissue activity; both sexes develop polydipsia and polyuria with reduced vasopressin levels. AgRP neurons from Cpt1aKO mice show reduced mitochondria and decreased presynaptic innervation to the paraventricular nucleus. AgRP neuron-specific Cpt1a knockout (tamoxifen-inducible AgRPCreERT2), metabolic phenotyping, calorimetry, AAV-mediated neuronal labeling, RiboTag ribosome profiling, single-nucleus RNA-seq Biology of sex differences High 36966335
2024 Tubule-specific Cpt1a deletion in mice does not significantly affect kidney function or fibrosis after aging or chronic injury; primary tubule cells lacking Cpt1a show modest reduction in palmitate oxidation but compensate through upregulation of peroxisomal FAO enzymes, suggesting peroxisomal β-oxidation compensates for loss of mitochondrial CPT1A-mediated FAO in tubules. Tubule-specific Cpt1a conditional KO mice, aristolochic acid and UUO injury models, 2-year aging, single-nuclear RNA-Seq, palmitate oxidation assays JCI insight High 38516886
2024 ALKBH5 demethylase removes m6A modification from CPT1A mRNA, enhancing its stability and upregulating CPT1A expression in macrophages, which promotes M2 macrophage polarization and FAO, facilitating colorectal cancer progression. Me-RIP assay, Actinomycin D mRNA stability assay, ALKBH5 gain-of-function, OCR measurement, co-culture CRC/macrophage model Experimental cell research Medium 38479704
2024 CPT1A promotes K63-type ubiquitination of IGF2BP1 via RNF5; IGF2BP1 then binds m6A sites on CPT1A mRNA and enhances its stability, creating a regulatory axis (PPARγ-RNF5-IGF2BP1-CPT1A) in steatotic hepatocellular carcinoma that sustains FAO. RNF5–IGF2BP1 interaction assays, K63-ubiquitination characterization, m6A-RIP for CPT1A mRNA, mRNA stability assays, PPARγ ChIP at RNF5 promoter, lipidomics, transcriptomics Cancer letters Medium 39734009
2024 PACS2 positively regulates CPT1A expression; PACS2 silencing downregulates CPT1A and upregulates DHODH, reversing HGPA-induced ferroptosis in cardiomyocytes. CPT1A agonist treatment in PACS2-silenced cells re-exacerbates ferroptosis and mitochondrial damage, placing CPT1A downstream of PACS2 in the PACS2/CPT1A/DHODH ferroptosis signaling pathway. PACS2 siRNA knockdown, CPT1A agonist rescue, ferroptosis markers (iron, lipid peroxides, ROS), STZ/HFD diabetic mouse model, cardiac function measurement Cardiovascular diabetology Medium 39633391
2024 Astragaloside IV (ASIV) restores CPT1A activity, which in turn mediates K99 succinylation of HSD17B10; this succinylation maintains mitochondrial RNase P stability by stabilizing the HSD17B10-MRPP1 interaction. K99R mutation of HSD17B10 disrupts its binding to CPT1A and MRPP1, impairs RNase P activity, and induces oxidative stress. Molecular docking and cell thermal shift assay suggest ASIV directly binds CPT1A. Succinylated proteomics, site-directed mutagenesis (K99R), molecular docking, cell thermal shift assay, Co-IP (HSD17B10–CPT1A, HSD17B10–MRPP1), RNase P activity assay, db/db mouse model Phytotherapy research Medium 39038923
2024 CPT1A anchors Bcl2 to the mitochondrial membrane in podocytes, preventing cytochrome C release and mitochondrial apoptosis; CPT1A also fosters lipid consumption via FAO, reducing lipotoxicity. FOXA1 is identified as a transcription factor for CPT1A in podocytes. CPT1A overexpression protects against albuminuria and glomerulosclerosis in diabetic mice. CPT1A overexpression, streptozotocin diabetic mouse model, Bcl2 mitochondrial localization assay, cytochrome C release assay, FOXA1 identification as upstream regulator Diabetes Medium 38506804
2012 A novel homozygous missense mutation R595W in CPT1A reduces CPT1A enzymatic activity by inducing steric hindrance: Arg595 contributes to a hydrogen-bond network with Cys304 and Met593, and its replacement by tryptophan causes steric clash with Ile480 in α-helix 12, disrupting protein architecture and function without directly affecting the catalytic site or carnitine pocket. CPT1A activity assay in patient fibroblasts, sequence alignment, protein structural modeling, comparison with known C304W mutant mechanism JIMD reports Medium 23430932
2023 CPT1A-mediated FAO promotes VEGF-C and VEGF-D expression in breast cancer cells and regulates VEGFR3 expression in lymphatic endothelial cells via acetyl-CoA-mediated H3K9 acetylation, promoting lymphangiogenesis; acetate supplementation rescues VEGFR3 expression upon CPT1A knockdown. CPT1A shRNA knockdown, LC-MS acetyl-CoA/CoA ratio measurement, VEGF-C/D and VEGFR3 expression analysis, H3K9ac analysis, acetate rescue, transwell and lymphatic vessel formation assays Biomedicine & pharmacotherapy Medium 29940537
2024 Coriobacteriaceae bacteria (Cori.ST1911) activate CPT1A and increase acylcarnitine levels in colorectal cancer cells via the CPT1A-ERK signaling pathway, promoting tumorigenesis; this was demonstrated in CRC cell lines, organoids, and multiple CRC mouse models. 16S rRNA and metagenomic sequencing, LC-MS/MS metabolomics, CRC cell/organoid co-culture with Coriobacteriaceae, CPT1A-ERK pathway analysis, multiple CRC mouse models NPJ biofilms and microbiomes Medium 38245554
2024 CPT1A mediates chemoresistance in hypopharyngeal squamous cell carcinoma by interacting with autophagy-related protein ATG16L1 and stimulating its succinylation, which drives autophagosome formation and autophagy; 3-methyladenine (autophagy inhibitor) or CPT1A inhibitor reduces cisplatin resistance. Co-immunoprecipitation (CPT1A–ATG16L1), succinylation assays, 3-MA autophagy inhibitor treatment, CPT1A inhibitor treatment, in vitro and in vivo cisplatin sensitivity assays Cell insight Medium 37961047
2022 STAT3/CPT1A-dependent FAO sustains hepatic stellate cell (HSC) proliferation and activation; cryptotanshinone inhibits STAT3 phosphorylation and nuclear translocation, reducing CPT1A expression and FAO (measured by ATP and acetyl-CoA reduction), with CPT1A overexpression reversing the anti-fibrotic effect. Transcriptomic sequencing, CPT1A and CPT1B expression analysis, STAT3 phosphorylation and nuclear translocation assay, ATP and acetyl-CoA measurement, CPT1A overexpression rescue, CCl4 mouse fibrosis model Chemico-biological interactions Medium 38936533

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential. Endocrinology 573 31900483
2018 Etomoxir Actions on Regulatory and Memory T Cells Are Independent of Cpt1a-Mediated Fatty Acid Oxidation. Cell metabolism 333 30043753
2018 CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. Oncogene 305 29995871
2021 Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis. The Journal of clinical investigation 286 33465052
2018 Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. Theranostics 229 29721083
2011 Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex. The Journal of biological chemistry 206 21622568
2015 Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. Blood 185 26276667
2010 Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. Molecular and cellular endocrinology 174 20638986
2024 Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer. Signal transduction and targeted therapy 166 38453925
2021 Butyrate enhances CPT1A activity to promote fatty acid oxidation and iTreg differentiation. Proceedings of the National Academy of Sciences of the United States of America 149 34035164
2019 CPT1A/2-Mediated FAO Enhancement-A Metabolic Target in Radioresistant Breast Cancer. Frontiers in oncology 137 31803610
2022 Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation. Theranostics 128 34976224
2023 Mitochondrial CPT1A: Insights into structure, function, and basis for drug development. Frontiers in pharmacology 119 37033619
2018 CPT1A-mediated succinylation of S100A10 increases human gastric cancer invasion. Journal of cellular and molecular medicine 119 30394687
2022 CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma. Cell death & disease 105 35411000
2024 ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis. Journal of translational medicine 90 38395901
2021 iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation. Molecular oncology 85 34213835
2020 Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 85 32666604
2023 CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing. Proceedings of the National Academy of Sciences of the United States of America 81 37722058
2016 High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia. EBioMedicine 79 27916548
2020 Upregulation of CPT1A is essential for the tumor-promoting effect of adipocytes in colon cancer. Cell death & disease 70 32913185
2023 Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner. International journal of biological sciences 69 36632454
2015 High fructose consumption induces DNA methylation at PPARα and CPT1A promoter regions in the rat liver. Biochemical and biophysical research communications 63 26519879
2022 CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis. Redox biology 61 36427397
2020 Carbohydrate and fat intake associated with risk of metabolic diseases through epigenetics of CPT1A. The American journal of clinical nutrition 59 32930325
2023 CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. Molecular cell 53 38016475
2021 Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell reports. Medicine 52 35028612
2014 High grade glioblastoma is associated with aberrant expression of ZFP57, a protein involved in gene imprinting, and of CPT1A and CPT1C that regulate fatty acid metabolism. Cancer biology & therapy 51 24618825
2018 Epigenetic regulation of carnitine palmitoyltransferase 1 (Cpt1a) by high fat diet. Biochimica et biophysica acta. Gene regulatory mechanisms 48 30605728
2023 L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways. Acta physiologica (Oxford, England) 47 37042471
2022 Rhein Improves Renal Fibrosis by Restoring Cpt1a-Mediated Fatty Acid Oxidation through SirT1/STAT3/twist1 Pathway. Molecules (Basel, Switzerland) 45 35408745
2021 Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling. Cell death and differentiation 44 34413485
2022 Inhibition of Cpt1a alleviates oxidative stress-induced chondrocyte senescence via regulating mitochondrial dysfunction and activating mitophagy. Mechanisms of ageing and development 43 35728631
2021 Fatty acid β-oxidation promotes breast cancer stemness and metastasis via the miRNA-328-3p-CPT1A pathway. Cancer gene therapy 43 34045663
2019 Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury. Cellular and molecular gastroenterology and hepatology 42 31654770
2018 CPT1A regulates breast cancer-associated lymphangiogenesis via VEGF signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 42 29940537
2005 Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. European journal of nutrition 40 16362726
2022 Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC. Acta biochimica et biophysica Sinica 37 35130611
2020 CPT1A Over-Expression Increases Reactive Oxygen Species in the Mitochondria and Promotes Antioxidant Defenses in Prostate Cancer. Cancers 37 33218188
2019 CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions. Cells 37 31547059
2021 Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis. Cell death discovery 36 34052835
2021 Hepatic CPT1A Facilitates Liver-Adipose Cross-Talk via Induction of FGF21 in Mice. Diabetes 36 34675003
2002 Organization of the human liver carnitine palmitoyltransferase 1 gene ( CPT1A) and identification of novel mutations in hypoketotic hypoglycaemia. Human genetics 36 12189492
2021 CPT1A and fatty acid β-oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer. NAR cancer 35 34514415
2017 CPT1A Missense Mutation Associated With Fatty Acid Metabolism and Reduced Height in Greenlanders. Circulation. Cardiovascular genetics 35 28611031
2024 Endogenous Coriobacteriaceae enriched by a high-fat diet promotes colorectal tumorigenesis through the CPT1A-ERK axis. NPJ biofilms and microbiomes 32 38245554
2024 CPT1A-IL-10-mediated macrophage metabolic and phenotypic alterations ameliorate acute lung injury. Clinical and translational medicine 32 39090662
2024 ALKBH5-mediated upregulation of CPT1A promotes macrophage fatty acid metabolism and M2 macrophage polarization, facilitating malignant progression of colorectal cancer. Experimental cell research 31 38479704
2024 PACS2/CPT1A/DHODH signaling promotes cardiomyocyte ferroptosis in diabetic cardiomyopathy. Cardiovascular diabetology 31 39633391
2023 A novel CPT1A covalent inhibitor modulates fatty acid oxidation and CPT1A-VDAC1 axis with therapeutic potential for colorectal cancer. Redox biology 30 37977042
2024 CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer. Cancer letters 29 38823763
2022 An integrated network pharmacology and cell metabolomics approach to reveal the role of rhein, a novel PPARα agonist, against renal fibrosis by activating the PPARα-CPT1A axis. Phytomedicine : international journal of phytotherapy and phytopharmacology 28 35567992
2024 ASS1 enhances anoikis resistance via AMPK/CPT1A-mediated fatty acid metabolism in ovarian cancer. Cancer letters 27 38914306
2020 Yin Zhi Huang, a traditional Chinese herbal formula, ameliorates diet-induced obesity and hepatic steatosis by activating the AMPK/SREBP-1 and the AMPK/ACC/CPT1A pathways. Annals of translational medicine 27 32309378
2022 The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2. Cell death discovery 26 35383152
2024 The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7. Cardiovascular diabetology 25 38195542
2020 Cpt1a promoted ROS-induced oxidative stress and inflammation in liver injury via the Nrf2/HO-1 and NLRP3 inflammasome signaling pathway. Canadian journal of physiology and pharmacology 25 32893669
2022 The role of CPT1A as a biomarker of breast cancer progression: a bioinformatic approach. Scientific reports 24 36180554
2022 Neutrophil trafficking to the site of infection requires Cpt1a-dependent fatty acid β-oxidation. Communications biology 24 36513703
2023 Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice. Gastroenterology report 23 37293270
2017 Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. Epilepsy research 23 28315807
2013 Effects of cannabinoid receptor 1 (brain) on lipid accumulation by transcriptional control of CPT1A and CPT1B. Animal genetics 23 23914904
1998 Chromosomal locations of the mouse fatty acid oxidation genes Cpt1a, Cpt1b, Cpt2, Acadvl, and metabolically related Crat gene. Mammalian genome : official journal of the International Mammalian Genome Society 23 9680378
2021 Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease. PPAR research 22 34306045
2019 CPT1A plays a key role in the development and treatment of multiple sclerosis and experimental autoimmune encephalomyelitis. Scientific reports 22 31527712
2025 CPT1A-mediated MFF succinylation promotes stemness maintenance in ovarian cancer stem cells. Communications biology 21 39956875
2023 CPT1A modulates PI3K/Akt/mTOR pathway to promote preeclampsia. Placenta 21 36702079
2023 Multi-tissue epigenetic analysis identifies distinct associations underlying insulin resistance and Alzheimer's disease at CPT1A locus. Clinical epigenetics 21 37891690
2023 Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease. Molecular and cellular endocrinology 21 38128823
2022 Vitamin D Counteracts Lipid Accumulation, Augments Free Fatty Acid-Induced ABCA1 and CPT-1A Expression While Reducing CD36 and C/EBPβ Protein Levels in Monocyte-Derived Macrophages. Biomedicines 21 35453525
2022 CPT1A-Mediated Fatty Acid Oxidation Promotes Precursor Osteoclast Fusion in Rheumatoid Arthritis. Frontiers in immunology 20 35273614
2020 LRRK2 Regulates CPT1A to Promote β-Oxidation in HepG2 Cells. Molecules (Basel, Switzerland) 20 32916992
2024 CPT1A Protects Podocytes From Lipotoxicity and Apoptosis In Vitro and Alleviates Diabetic Nephropathy In Vivo. Diabetes 19 38506804
2024 Tubular CPT1A deletion minimally affects aging and chronic kidney injury. JCI insight 19 38516886
2022 Dual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres. Journal of neuro-oncology 19 36396930
2016 CPT1A methylation is associated with plasma adiponectin. Nutrition, metabolism, and cardiovascular diseases : NMCD 19 28139377
2012 Variants in CPT1A, FADS1, and FADS2 are Associated with Higher Levels of Estimated Plasma and Erythrocyte Delta-5 Desaturases in Alaskan Eskimos. Frontiers in genetics 19 22701466
2023 Restoration of CPT1A-mediated fatty acid oxidation in mesothelial cells protects against peritoneal fibrosis. Theranostics 18 37649600
2024 RNF5 exacerbates steatotic HCC by enhancing fatty acid oxidation via the improvement of CPT1A stability. Cancer letters 17 39734009
2023 CPT1A mediates chemoresistance in human hypopharyngeal squamous cell carcinoma via ATG16L1-dependent cellular autophagy. Cell insight 17 37961047
2022 WY-14643 attenuates lipid deposition via activation of the PPARα/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC. Lipids in health and disease 17 36384580
2016 Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation. The international journal of biochemistry & cell biology 17 27793752
2024 TM7SF2-induced lipid reprogramming promotes cell proliferation and migration via CPT1A/Wnt/β-Catenin axis in cervical cancer cells. Cell death discovery 16 38693136
2023 FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation. Frontiers in oncology 16 37207154
2023 Resensitizing Paclitaxel-Resistant Ovarian Cancer via Targeting Lipid Metabolism Key Enzymes CPT1A, SCD and FASN. International journal of molecular sciences 16 38003694
2020 MiRNA-324-5p inhibits inflammatory response of diabetic vessels by targeting CPT1A. European review for medical and pharmacological sciences 15 33378033
2007 Lack of association of CPT1A polymorphisms or haplotypes on hepatic lipid content or insulin resistance in Japanese individuals with type 2 diabetes mellitus. Metabolism: clinical and experimental 15 17445541
2024 Astragaloside IV protects renal tubular epithelial cells against oxidative stress-induced injury by upregulating CPT1A-mediated HSD17B10 lysine succinylation in diabetic kidney disease. Phytotherapy research : PTR 14 39038923
2012 A Novel Mutation in CPT1A Resulting in Hepatic CPT Deficiency. JIMD reports 14 23430932
2024 Hypoxia expedites the progression of papillary thyroid carcinoma by promoting the CPT1A-mediated fatty acid oxidative pathway. Drug development research 13 38450796
2023 CPT1A in AgRP neurons is required for sex-dependent regulation of feeding and thirst. Biology of sex differences 13 36966335
2024 FTY720 ameliorates experimental MPO-ANCA-associated vasculitis by regulating fatty acid oxidation via the neutrophil PPARα-CPT1a pathway. Rheumatology (Oxford, England) 12 38837706
2023 Expression Variation of CPT1A Induces Lipid Reconstruction in Goat Intramuscular Precursor Adipocytes. International journal of molecular sciences 12 37686221
2022 Sinomenine Ameliorates Colitis-Associated Cancer by Modulating Lipid Metabolism via Enhancing CPT1A Expression. Metabolites 12 36295848
2021 Infusion of Phagocytic Macrophages Overexpressing CPT1a Ameliorates Kidney Fibrosis in the UUO Model. Cells 12 34209378
2020 Inuit metabolism revisited: what drove the selective sweep of CPT1a L479? Molecular genetics and metabolism 12 32088118
2024 Cryptotanshinone alleviates liver fibrosis via inhibiting STAT3/CPT1A-dependent fatty acid oxidation in hepatic stellate cells. Chemico-biological interactions 11 38936533
2024 CircITGB5 regulates the proliferation and adipogenic differentiation of chicken intramuscular preadipocytes through the miR-181b-5p/CPT1A axis. International journal of biological macromolecules 11 39577521
2023 DNA Methylation Near CPT1A and Changes in Triglyceride-rich Lipoproteins in Response to Weight-loss Diet Interventions. The Journal of clinical endocrinology and metabolism 11 36800272
2023 IL-37 Ameliorates Renal Fibrosis by Restoring CPT1A-Mediated Fatty Acid Oxidation in Diabetic Kidney Disease. Kidney diseases (Basel, Switzerland) 10 37065609

Missed literature

Know a paper Affinage missed for CPT1A? Flag it for the maintainers and the community.

No submissions yet.